

Burt Adelman, M.D.

Dr. Adelman is a Distinguished Fellow at MIT's Center for Biomedical Innovations. Previously, he served as Executive Vice President of Research & Development at Biogen Idec from 2001 to 2006. He joined the company in 1991 as Director of Medical Research and was given roles of increasing responsibility overseeing the Preclinical Development, Medical Operations and Regulatory Affairs groups. He led development and regulatory efforts for four currently marketed drugs: ANGIOMAX®, AVONEX®, AMEVIVE®, and TYSABRI®. Prior to joining Biogen, Dr. Adelman was Associate Professor of Medicine, Medical College of Virginia, and Chief of the Hematology Service, Hunter Holmes McGuire Department of Veteran's Affairs Medical Center in Richmond, VA.

Dr. Adelman is also a Lecturer in Medicine at Harvard Medical School and a member of the Hematology/Oncology Division of the Department of Medicine, Brigham & Women's Hospital. He is currently a member of various boards of directors, including the New England Healthcare Institute and the New England Division of the American Cancer Society.

Dr. Adelman received a B.S. in biology from Trinity College and an M.D. from Cornell Medical College.

Howard L. Golub, M.D., Ph.D.

Dr. Golub is a Distinguished Fellow at CBI. He is also an independent consultant and a senior lecturer in the MIT-Harvard Joint Program (H.S.T.). He has an adjunct appointment at the Boston University School of Public Health in biostatistics and epidemiology and has been the principal investigator on two large National Institutes of Health trials.

In 1995, Dr. Golub co-founded and became President of CareStat Inc., a full-service clinical research organization. After CareStat was acquired by Battelle Memorial Institute in 2005, he served as president of the clinical trials subsidiary until 2008.

He has served as a founder and chief of several companies devoted to the development of various diagnostic medical devices and tests, specialized computer software and the provision of management services to a fully-integrated physician network.

Dr. Golub received a Ph.D. in bioelectrical engineering from MIT in 1979 and medical degree from Harvard Medical School (MIT-Harvard Joint Program: H.S.T.) in 1983.

James C. Leung, Ph.D.

Dr. Leung is a Visiting Scientist at MIT participating in biotechnology research projects in the Biology and Chemical Engineering departments. He also engages with biotechnology and pharmaceutical companies by serving as consulting advisor in the areas of biotherapeutic development and manufacturing.

For the last ten years, Dr. Leung was the Vice President of Biotechnology at Ipsen, an international pharmaceutical company headquartered in France and the United Kingdom. Prior to Ipsen, from 1995 to 1998, he worked as an independent consultant advising startup biotechnology companies in the United States and Asia, and served as industrial coordinator for two consortia at MIT – BioProcess Engineering Center (BPEC) and Consortium for the Advanced Manufacturing of Pharmaceuticals (CAMP).

From 1993 to 1995, Dr. Leung was the Senior Vice President of Operations at Repligen Corp., a public biotechnology company focused on developing novel therapeutics for neurological disorders. Dr. Leung started his biotechnology career at Genentech, Inc.

Dr. Leung received a B.Sc. degree from the Chemical Engineering Department at MIT, and a M.Sc. degree and a Ph.D. degree in biochemical engineering from MIT.

G.K. Raju, Ph.D.

Dr. Raju is Executive Director of the Pharmaceutical Manufacturing Initiative (PHARMI) within the Program on the Pharmaceutical Industry (now merged with CBI) at MIT. and Chairman of the Bio-manufacturing Steering Committee at the Center for Biomedical Innovation (CBI) at MIT. He is also Adjunct Professor of Industrial Pharmacy at Purdue University. He is Chairman and CEO of Light Pharma Incorporated - a consulting and technology company that is focused on pharmaceutical and biotechnology manufacturing. In addition, Dr. Raju is the Executive Director of the Consortium for the Advancement of Manufacturing of Pharmaceuticals (CAMP). He is also a Special Government Employee (SGE) of the U.S. Food and Drug Administration and a member of the Process Analytical Technology (PAT) and Manufacturing Subcommittees for the FDA Pharmaceutical Science Advisory Committee. Dr. Raju obtained his M.S. in Chemical Engineering from MIT in 1989, his MBA from the MIT Sloan School of Management in 1994 and Ph.D. in Chemical Engineering from MIT in 1998.

Dr. Raju has worked with or consulted for most of the top pharmaceutical and biotechnology companies. His expertise is in defining the strategic role of pharmaceutical development and manufacturing and enabling its performance with the pharmaceutical and biotechnology industry. He has benchmarked the pharmaceutical and biotechnology industry's manufacturing practices for a large number of years and has been involved in multiple organizational transformation efforts. His work focuses on pharmaceutical process innovation and addresses issues of manufacturing science, regulatory compliance, six sigma, operational excellence, systems dynamics, organizational learning, process analytical technology, on-line sensors, economic modeling, data analysis, pattern recognition and knowledge based systems. Dr. Raju's work makes extensive use of simulation. He is the author of several publications and book chapters.

Dr. Raju received an M.S. in business management from the MIT Sloan School of Management in 1994 and a Ph.D. from the MIT Department of Chemical Engineering in 1998.

Wayne A. Rosenkrans, Jr., Ph.D.

Dr. Rosenkrans is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and medicine. He is also Chairman and President of the Personalized Medicine Coalition, a Washington D.C. - based organization working with government and other agencies on evolving healthcare policy for personalized healthcare; Chief Applications Officer for SciTech Strategies focusing on scientific competency and capacity development for academia and industry; and Vice President of Healthcare Strategy at Fuld and Co. focusing on strategic simulations in healthcare.

He is a former Director of External Relations for the Personalized Healthcare Team and Evidence-based Medicine (EBM) as part of External Medical Relations at AstraZeneca where he was responsible for long-range external relations strategy and policy development. He has presented at numerous forums on aspects of personalized healthcare, evidence-based medicine, new development paradigms, and strategy development.

Dr. Rosenkrans received an S.B. in biology from MIT, a Ph.D. in cell and molecular biology from Boston University, and received post-doctoral training in cancer and radiation biology at the University of Rochester.